Zenotech Laboratories Ltd (ZENOTECH) is currently trading at 44.99 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Zenotech Laboratories Limited specializes in manufacturing pharmaceutical specialty generic injectables. It serves therapeutic areas such as oncology and anesthesiology, providing critical care solutions. The company has undergone multiple mergers, significantly enhancing its product portfolio, particularly in oncology, with 15 generic chemical oncology products launched in India. Zenotech's strategic collaboration with Sun Pharmaceutical Industries Limited has resulted in leasing its biotech API facility for R&D activities, reflecting a focus on innovation and growth. Post its merger with Ranbaxy, Zenotech is under the influence of large promoters, including Daiichi Sankyo, positioning it advantageously in the pharmaceutical sector.

Over the past 52 weeks, Zenotech Laboratories Ltd has traded between a low of ₹33.55 and a high of ₹56.99. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Zenotech Laboratories Ltd has a market capitalization of approximately 282.33. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Zenotech Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -112.04 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 282.33 Cr, Zenotech Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Zenotech Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Zenotech Laboratories Ltd is -112.04. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Zenotech Laboratories reported a standalone net loss of ₹0.46 crore for the quarter ended June 30, 2026 (Q1FY26), based on the provided figures.